Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells

被引:30
作者
Chatain, N. [1 ]
Ziegler, P. [2 ]
Fahrenkamp, D. [1 ]
Jost, E. [2 ]
Moriggl, R. [3 ]
Schmitz-Van de Leur, H. [1 ]
Mueller-Newen, G. [1 ]
机构
[1] Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, D-52074 Aachen, NRW, Germany
[2] Rhein Westfal TH Aachen, Klin Onkol Hamatol & Stammzelltransplantat, D-52074 Aachen, NRW, Germany
[3] Ludwig Boltzmann Inst Canc Res LBI CR, Vienna, Austria
关键词
CML; BCR-ABL; STAT5; Src; inhibitors; CHRONIC MYELOID-LEUKEMIA; DNA-BINDING ACTIVITY; SIGNAL TRANSDUCERS; CONSTITUTIVE ACTIVATION; LYMPHOBLASTIC-LEUKEMIA; PHOSPHORYLATED STAT5; TRANSCRIPTION STAT; INHIBITS APOPTOSIS; TYROSINE KINASE; SURVIVAL;
D O I
10.1038/onc.2012.369
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Persistent activation of the Abl tyrosine kinase in the BCR-ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR-ABL phosphorylates STAT5 and Src family kinases (SFK). Activated pSTAT5 is essential for initial transformation and maintenance of the disease. Cytokine-induced phosphorylation on tyrosine 694 typically leads to nuclear accumulation of pSTAT5 and target gene expression. We verified that in BCR-ABL-positive progenitor cells from a CML patient and in K562 cells pSTAT5 is cytoplasmic. However, upon ectopic expression of BCR-ABL p210 in non-myeloid cells, co-transfected STAT5A is phosphorylated on Y694 and localized in the nucleus arguing for an additional factor mediating cytoplasmic retention in CML cells. Expression of the SFK v-Src, Hck or Lyn together with STAT5A results in phosphorylation on Y694 and cytoplasmic retention. Upon coexpression of BCR-ABL and individual SFK the cytoplasmic retention of activated STAT5A mediated by v-Src and Hck but not Lyn is dominant over nuclear translocation induced by BCR-ABL. Cytoplasmic retention depends on the kinase activity of SFK and is mediated through the interaction of the SH2 domain of STAT5A with the SFK. Interestingly, nuclear accumulation of STAT5A as a result of activation by FLT3-ITD, an oncogene found in acute myeloid leukemia, cannot be prevented by coexpression of SFK. Importantly, inhibition of SFK in K562 cells restored nuclear accumulation of pSTAT5A, enhanced STAT5 target gene expression and increased colony formation. Thus, SFK mediate cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells. Cytoplasmic pSTAT5A in CML cells might balance the controversial functions of STAT5 in cellular senescence and differentiation versus G(1)/S progression and survival.
引用
收藏
页码:3587 / 3597
页数:11
相关论文
共 48 条
[1]   Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis [J].
Baumgartner, Christian ;
Cerny-Reiterer, Sabine ;
Sonneck, Karoline ;
Mayerhofer, Matthias ;
Gleixner, Karoline V. ;
Fritz, Richard ;
Kerenyi, Marc ;
Boudot, Cedric ;
Gouilleux, Fabrice ;
Kornfeld, Jan-Wilhelm ;
Sillaber, Christian ;
Moriggl, Richard ;
Valent, Peter .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (06) :2416-2429
[2]   Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD [J].
Bunting, Kevin D. ;
Xie, Xiu Yan ;
Warshawsky, Iika ;
Hsi, Eric D. .
BLOOD, 2007, 110 (07) :2775-2776
[3]   STAT5 signaling in normal and pathologic hematopoiesis [J].
Bunting, Kevin D. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :2807-2820
[4]   Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl [J].
Carlesso, N ;
Frank, DA ;
Griffin, JD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :811-820
[5]   Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes [J].
Choudhary, Chunaram ;
Olsen, Jesper V. ;
Brandts, Christian ;
Cox, Jurgen ;
Reddy, Pavankurnar N. G. ;
Boehmer, Frank D. ;
Gerke, Volker ;
Schmidt-Arras, Dirk-E. ;
Berdel, Wolfgang E. ;
Mueller-Tidow, Carsten ;
Mann, Matthias ;
Serve, Hubert .
MOLECULAR CELL, 2009, 36 (02) :326-339
[6]   Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction [J].
Copland, Mhairi ;
Hamilton, Ashley ;
EIrick, Lucy J. ;
Baird, Janet W. ;
Allan, Elaine K. ;
Jordanides, Niove ;
Barow, Martin ;
Mountford, Joanne C. ;
Holyoake, Tessa L. .
BLOOD, 2006, 107 (11) :4532-4539
[7]   Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib [J].
Cortes, Jorge E. ;
Kantarjian, Hagop M. ;
Bruemmendorf, Tim H. ;
Kim, Dong-Wook ;
Turkina, Anna G. ;
Shen, Zhi-Xiang ;
Pasquini, Ricardo ;
Khoury, H. Jean ;
Arkin, Steven ;
Volkert, Angela ;
Besson, Nadine ;
Abbas, Richat ;
Wang, Junyuan ;
Leip, Eric ;
Gambacorti-Passerini, Carlo .
BLOOD, 2011, 118 (17) :4567-4576
[8]   Mutational switch of an IL-6 response to an interferon-γ-like response [J].
Costa-Pereira, AP ;
Tininini, S ;
Strobl, B ;
Alonzi, T ;
Schlaak, JF ;
Is'harc, H ;
Gesualdo, I ;
Newman, SJ ;
Kerr, IM ;
Poli, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) :8043-8047
[9]  
DanhauserRiedl S, 1996, CANCER RES, V56, P3589
[10]   The molecular biology of chronic myeloid leukemia [J].
Deininger, MWN ;
Goldman, JM ;
Melo, JV .
BLOOD, 2000, 96 (10) :3343-3356